5.16
-0.16 (-3.01%)
| Previous Close | 5.32 |
| Open | 5.22 |
| Volume | 213,424 |
| Avg. Volume (3M) | 264,325 |
| Market Cap | 272,818,144 |
| Price / Sales | 2.22 |
| Price / Book | 2.48 |
| 52 Weeks Range | |
| Earnings Date | 4 Mar 2026 |
| Profit Margin | -63.24% |
| Operating Margin (TTM) | -79.16% |
| Diluted EPS (TTM) | -0.980 |
| Quarterly Revenue Growth (YOY) | -9.10% |
| Total Debt/Equity (MRQ) | 52.12% |
| Current Ratio (MRQ) | 10.47 |
| Operating Cash Flow (TTM) | -24.17 M |
| Levered Free Cash Flow (TTM) | -8.84 M |
| Return on Assets (TTM) | -21.77% |
| Return on Equity (TTM) | -52.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Sight Sciences, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.63 |
|
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 20.87% |
| % Held by Institutions | 50.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kck Ltd. | 30 Sep 2025 | 4,374,975 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (UBS, 113.18%) | Buy |
| Median | 8.50 (64.73%) | |
| Low | 6.50 (Citigroup, 25.97%) | Hold |
| Average | 8.63 (67.25%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 5.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 06 Mar 2026 | 6.50 (25.97%) | Hold | 3.71 |
| UBS | 06 Mar 2026 | 11.00 (113.18%) | Buy | 3.71 |
| Stifel | 02 Mar 2026 | 8.00 (55.04%) | Buy | 5.62 |
| Piper Sandler | 05 Jan 2026 | 9.00 (74.42%) | Buy | 7.71 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2026 | Announcement | Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |